Abimab Snags $8.2M in Equity
Luke Timmerman10/6/09
Adimab, the Lebanon, NH-based developer of technology to quickly make antibody drugs, has raised $8.2 million in a venture round, according to a regulatory filing. Adimab collected the Series D financing from Google Ventures, SV Life Sciences, Polaris Venture Partners, OrbiMed Advisors, and Borealis Ventures, as Ryan reported last week before the dollar amount became public. Adimab is led by CEO Tillman Gerngross, who sold his previous antibody company, GlycoFi, to Merck for $400 million in 2006.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
